FindTrial
Sign In

CIK cells

DRUG3 trials

Sponsors

Sally Arai, Everett Meyer, Tianjin Medical University Cancer Institute and Hospital

Conditions

AnemiaBone Marrow Transplant FailureClear Cell Renal Cell CarcinomaLeukemiaLeukemia, MyeloidMultiple MyelomaMyelodysplastic Syndromes (MDS)Myeloproliferative Disorders

Phase 1

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
CompletedNCT00477035
Sally AraiLeukemia, Multiple Myeloma
Start: 2006-05-31End: 2011-03-31Updated: 2017-01-11

Phase 2

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
CompletedNCT01392989
Everett MeyerAnemia, Bone Marrow Transplant Failure, Leukemia, Myeloid +3
Start: 2011-03-31End: 2017-03-19Updated: 2019-05-07
Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma
NCT03987698
Tianjin Medical University Cancer Institute and HospitalClear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Start: 2019-06-01End: 2022-06-01Target: 90Updated: 2020-07-07

Related Papers

Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms
Biology of Blood and Marrow Transplantation2019-04-0222 citations
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
2015-02-0637 citations